Tonix Pharmaceuticals Holding - נכסים נקיים למניה בודדת TNXP

Tonix Pharmaceuticals (TNXP) develops advanced vaccines and small molecules for the treatment of CNS diseases and infections, leveraging a robust scientific foundation. Stability of raw material supplies is ensured through an extensive network of global routes, eliminating the risk of shortages. The price trend featuring the 13.27 metric demonstrates market dynamics, while multi-year trials and strict government oversight create significant barriers to entry.

The book value per share reflects the net assets of Tonix Pharmaceuticals (TNXP) minus all liabilities, determining the actual value of a single security from a capital perspective. By analyzing the book value per share, an investor can assess the financial stability of Tonix Pharmaceuticals (TNXP) while it conducts costly clinical trials for CNS and immunology therapies, thereby avoiding speculative overpayment for the asset.